Polyrizon Ltd. (PLRZ) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 59.5 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PLRZ currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.53) and Max Pain ($9.45) forces dealer call-delta covering toward $19.11.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Polyrizon Ltd. (PLRZ) surged +4.57% to $9.00, trading at 40% of its 52-week range ($2.88 – $18.2). Stretched risk/reward at current multiples (-25% return on capital) under elevated 10-year interest-rate pressure.
All 120 planned participants randomized across five clinical sites in the United States Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage bi
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful
Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by 14.41% to
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PLRZ today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PLRZ. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Polyrizon Ltd. (PLRZ) ranks #590 by composite RQD confidence (42/100, grade D-) and #825 by equity capitalization ($21.9M). Within this direct 5-issuer industry benchmark cohort, PLRZ leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with PLRZ at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PLRZ
ACTIVE
Polyrizon Ltd. | D- | 42/100 | — | — | -25.1% | +4.57% | $21.9M | Benchmark Subject |
| NSPR InspireMD Inc. | D- | 38/100 | — | 29.5% | -35.0% | -3.55% | $21.0M | /nspr-vs-plrz → |
| PMI Picard Medical Inc. | C- | 61/100 | — | — | — | +12.17% | $19.9M | /pmi-vs-plrz → |
| RVP Retractable Technologies Inc. | E | 33/100 | — | 0.1% | -23.3% | -1.15% | $17.3M | /rvp-vs-plrz → |
| MODD Modular Medical Inc. | D- | 36/100 | — | — | -35.0% | -9.95% | $16.3M | /modd-vs-plrz → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Polyrizon Ltd. (PLRZ) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$3.3M, operating cash flow of -$4.5M, and free cash flow of -$4.5M (-295.4% YoY). On the balance sheet, PLRZ closed FY2025 with $21.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$3.3M | -$4.5M | -$4.5M | $21.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$1.5M | -$1.1M | -$1.1M | $5.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$600.0K | -$537.0K | -$537.0K | — | — |
As of 2026-11-01, Polyrizon Ltd. (NASDAQ: PLRZ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $9.00 (+4.57% 1D, market cap $21.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLRZ ranks #590 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), PLRZ carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -25.1%. By comparison, NSPR (InspireMD Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $21.0M) and PMI (Picard Medical Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $19.9M). Among the 5-stock peer group, PLRZ leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).
Per PLRZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001893645), Polyrizon Ltd. generated $0 in revenue, -$3.3M in net income, and -$4.5M in free cash flow against $21.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PLRZ last traded at $9.00 (+4.57% on volume of 8,299 shares), positioning the stock -14.53% below its 50-day simple moving average ($10.53) and -28.74% below its 200-day simple moving average ($12.63). Across its 52-week range of $2.88 to $18.20, PLRZ sits at the 39.9% percentile with a 14-day RSI of 59.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($7.87 to $10.13).
Why PLRZ Stock surged +4.57% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-25% return on capital) under elevated 10-year interest-rate pressure.